Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Prophylactic Measures

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the need for continued evaluation of prophylactic treatments like tocilizumab and antimicrobial measures for bispecific T-cell engagers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Management Strategies

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Awareness of AEs

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique AEs like CRS and the need for well-defined protocols.

Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Overview

October 21st 2024

In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss bispecific T-cell engagers, highlighting their effectiveness in treating hematologic malignancies like multiple myeloma, their potential use in solid tumors, and the importance of managing unique toxicities.

Selinexor Receives Approval in South Korea for Multiple Myeloma

October 18th 2024

The South Korean Ministry of Food and Drug Safety approved selinexor plus bortezomib and dexamethasone for pretreated patients with multiple myeloma.

Dr Corre on the Clinical Implications of D-VTd Treatment in Newly Diagnosed Myeloma

October 18th 2024

Jill Corre, PharmD, PhD, discusses the implications of using daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.

Daratumumab/Lenalidomide Maintenance Deepens Responses, Boosts MRD-Negativity Rates in Myeloma After ASCT

October 17th 2024

Ashraf Z. Badros, MBCHB, discusses the use of daratumumab plus lenalidomide as maintenance therapy after transplant in newly diagnosed multiple myeloma.

Dr Corre on the Rationale for the CASSIOPEIA Trial in Newly Diagnosed Myeloma

October 17th 2024

Jill Corre, PharmD, PhD, discusses the CASSIOPEIA trial of daratumumab plus bortezomib, thalidomide, and dexamethasone in newly diagnosed myeloma.

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

October 14th 2024

Dr. Saad Usmani discusses the results of the Phase 3 CEPHEUS study, which evaluated the combination of daratumumab with bortezomib/lenalidomide/dexamethasone (D-VRd) in transplant-ineligible or transplant-deferred patients with newly diagnosed multiple myeloma, highlighting its impact on progression-free survival and minimal residual disease negativity.

Dr Krishnan on the Optimal Use of DKd in Relapsed/Refractory Multiple Myeloma

October 11th 2024

Amrita Krishnan, MD, discusses the role of DKd for patients with relapsed/refractory multiple myeloma.

Dr Lentzsch on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

October 11th 2024

Suzanne Lentzsch, MD, PhD, discusses the safety profile of linvoseltamab in patients with relapsed/refractory multiple myeloma.

EU Approval Sought for D-VRd in Newly Diagnosed Myeloma

October 10th 2024

A Type II variation application has been submitted to the EMA for subcutaneous daratumumab plus VRd in newly diagnosed multiple myeloma.

Dr Banerjee on Future Hopes For Bispecific Antibody Therapy in Myeloma

October 8th 2024

Rahul Banerjee, MD, FACP, discusses his hopes for the future of bispecific antibody therapy for patients with multiple myeloma.

D-VRd Propels Toward SOC Status in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma

October 8th 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, expands on data from the CEPHEUS trial of D-VRd in transplant-ineligible/-deferred, newly diagnosed multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

OncLive’s September Roundup of Key FDA Approvals in Oncology

October 4th 2024

Here is your snapshot of all treatment options that the FDA approved in September 2024.

Dr Chari on the Risks and Benefits Associated With Earlier CAR T Use in R/R Multiple Myeloma

October 4th 2024

Ajai Chari, MD, discusses the potential role for CAR T-cell therapies in the early-relapsed setting for patients with multiple myeloma.

Dr Usmani on Challenges With Bispecifics and CAR T-Cell Therapies in Multiple Myeloma

October 3rd 2024

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses challenges of integrating bispecific antibodies and CAR T-cell therapies into the community for myeloma.

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

October 2nd 2024

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

October 2nd 2024

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.